Tag Archives: drug marketing

Deceptive drug research practices explain why over-medicating of children still going on

Share A new report from the U.S. Government Accountability office confirms something that Rose Firestein, the eponymous prosecutor in the title of Side Effects: A Prosecutor, a Whistleblower and Bestselling Antidepressant on Trial noticed way back in the ’90s: that … Continue reading

Posted in antidepressants, antipsychotic drugs, clinical trials, conflicts of interest, drug marketing, FDA, ghostwriting, pharmaceutical industry | Tagged , , , , , , | 3 Comments

International group seeks Brown University’s help in retracting controversial Paxil study

Share The international research organization Healthy Skepticism has called on Brown University to help convince a psychiatric journal to retract the controversial Paxil trial that I wrote about in Side Effects, according to the Brown Daily Herald. The principal investigator … Continue reading

Posted in antidepressants, conflicts of interest, drug marketing, ghostwriting, pharmaceutical industry, scientific journal retractions, scientific misconduct | Tagged , , , , , , , | 3 Comments

New heart medication study was too flawed for publication, former journal editor says

Share At a Harvard event last night honoring the former Grassley investigator Paul Thacker, someone in the audience wanted to know how the topic of Thacker’s talk — Dollars for Doctors: Who owns your physician? — was related to the … Continue reading

Posted in conflicts of interest, health care costs | Tagged , , , , , , , , | 9 Comments